ALXN stock forecast
Our latest prediction for Alexion Pharmaceuticals, Inc.'s stock price was made on the July 10, 2018 when the stock price was at 131.91$.
In the short term (2weeks), ALXN's stock price should underperform the market by -0.12%. During that period the price should oscillate between -3.93% and +3.81%.
In the medium term (3months), ALXN's stock price should outperform the market by 1.04%. During that period the price should oscillate between -9.37% and +11.57%.Get email alerts
About Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.
At the moment the company generates 4340M USD in revenues.
On its last earning announcement, the company reported a profit of 1.85$ per share.
The book value per share is 39.34$
Three months stock forecastJuly 10, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|